Mandy van Brakel

5PUBLICATIONS
47CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 06, 2026
Automated Computational Flow Cytometry Correlates Decreasing Neutrophil-to-Lymphocyte Ratio to Improved Survival in NSCLC After Immune Checkpoint Blockade.

|Apr 06, 2026
Multivalent Atezolizumab-Liposome Conjugates as Active Immunotherapeutic Platforms for Enhanced PD-L1 Blockade in Melanoma.

Ziyun Cheng, Mohamadreza Amin, Mandy van Brakel

|Feb 26, 2025
CXCL10 Secreted by Pericytes Mediates TNFα-Induced Vascular Leakage in Tumors and Enhances Extravasation of Nanoparticle-Based Chemotherapeutics.

Ann L B Seynhaeve, Hui Liu, Marjolein I Priester

|Aug 22, 2024
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

Dian Kortleve, Dora Hammerl, Mandy van Brakel

|Aug 05, 2016
MAGE-C2-Specific TCRs Combined with Epigenetic Drug-Enhanced Antigenicity Yield Robust and Tumor-Selective T Cell Responses.

Andre Kunert, Mandy van Brakel, Sabine van Steenbergen-Langeveld

Pageof 1

Frequent Collaborators

4 joint publications

Reno Debets

2 joint publications

Cor Lamers

2 joint publications

Timo L M Ten Hagen

2 joint publications

Ann L B Seynhaeve